Where Will Planet Labs Stock Be in 3 Years?
Planet Labs is far from a typical satellite-imager company. Founded…
Sell
44
WST Quote, Financials, Valuation and Earnings
Last price:
$250.54
Seasonality move
:
0.37%
Day range:
$248.88 - $254.27
52-week range:
$187.43 - $352.33
Dividend yield:
0.33%
P/E ratio:
37.60x
P/S ratio:
6.20x
P/B ratio:
6.17x
Volume:
445.3K
Avg. volume:
588.7K
1-year change:
-14.83%
Market cap:
$18.1B
Revenue:
$2.9B
EPS (TTM):
$6.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$730.1M | $1.54 | 5.56% | -9.13% | $316.36 |
|
ARAY
Accuray, Inc.
|
$124.5M | $0.02 | -9.18% | -62.5% | $5.50 |
|
BSX
Boston Scientific Corp.
|
$4.9B | $0.73 | 17.91% | 122.99% | $124.27 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.4B | $1.92 | 17.95% | 27.77% | $582.10 |
|
MASI
Masimo Corp.
|
$368.6M | $1.22 | -27.29% | 567.36% | $187.57 |
|
PODD
Insulet Corp.
|
$612.3M | $0.92 | 24.52% | 5.85% | $355.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$251.14 | $316.36 | $18.1B | 37.60x | $0.21 | 0.33% | 6.20x |
|
ARAY
Accuray, Inc.
|
$1.55 | $5.50 | $174.6M | 149.00x | $0.00 | 0% | 0.35x |
|
BSX
Boston Scientific Corp.
|
$108.14 | $124.27 | $160.2B | 64.37x | $0.00 | 0% | 8.72x |
|
ISRG
Intuitive Surgical, Inc.
|
$466.86 | $582.10 | $167.4B | 65.11x | $0.00 | 0% | 18.57x |
|
MASI
Masimo Corp.
|
$147.19 | $187.57 | $8B | 116.80x | $0.00 | 0% | 4.31x |
|
PODD
Insulet Corp.
|
$349.94 | $355.17 | $24.6B | 106.36x | $0.00 | 0% | 10.86x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
9.52% | 1.167 | 1.96% | 1.85x |
|
ARAY
Accuray, Inc.
|
68.48% | 1.945 | 114.29% | 0.74x |
|
BSX
Boston Scientific Corp.
|
34.92% | 0.666 | 7.55% | 0.69x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.124 | -- | 3.91x |
|
MASI
Masimo Corp.
|
38.11% | 1.252 | 7.03% | 0.79x |
|
PODD
Insulet Corp.
|
49.21% | 1.947 | 6.41% | 1.55x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$273.2M | $158.2M | 16.08% | 17.9% | 20.65% | $101.9M |
|
ARAY
Accuray, Inc.
|
$39M | $4.2M | -0.62% | -2.96% | 3.32% | -$13.1M |
|
BSX
Boston Scientific Corp.
|
$3.2B | $922M | 7.53% | 11.49% | 18.22% | $1.1B |
|
ISRG
Intuitive Surgical, Inc.
|
$1.6B | $743.4M | 15.96% | 15.98% | 30.47% | $560.1M |
|
MASI
Masimo Corp.
|
$233.3M | $64.5M | -12.68% | -21.09% | 17.39% | $64.5M |
|
PODD
Insulet Corp.
|
$456.4M | $121.1M | 8.78% | 19.28% | 18.66% | $173.3M |
West Pharmaceutical Services, Inc. vs. Competitors
-
Which has Higher Returns WST or ARAY?
Accuray, Inc. has a net margin of 17.2% compared to West Pharmaceutical Services, Inc.'s net margin of 0.88%. West Pharmaceutical Services, Inc.'s return on equity of 17.9% beat Accuray, Inc.'s return on equity of -2.96%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.35.66% $1.82 $3.2B ARAYAccuray, Inc.30.56% $0.01 $257.5M -
What do Analysts Say About WST or ARAY?
West Pharmaceutical Services, Inc. has a consensus price target of $316.36, signalling upside risk potential of 24.97%. On the other hand Accuray, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 254.84%. Given that Accuray, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Accuray, Inc. is more attractive than West Pharmaceutical Services, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.9 2 0 ARAYAccuray, Inc.3 0 0 -
Is WST or ARAY More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.054, which suggesting that the stock is 5.449% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.431%.
-
Which is a Better Dividend Stock WST or ARAY?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 0.33%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays -12% of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WST or ARAY?
West Pharmaceutical Services, Inc. quarterly revenues are $766.2M, which are larger than Accuray, Inc. quarterly revenues of $127.5M. West Pharmaceutical Services, Inc.'s net income of $131.8M is higher than Accuray, Inc.'s net income of $1.1M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 37.60x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.20x versus 0.35x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.20x 37.60x $766.2M $131.8M ARAYAccuray, Inc.0.35x 149.00x $127.5M $1.1M
-
Which has Higher Returns WST or BSX?
Boston Scientific Corp. has a net margin of 17.2% compared to West Pharmaceutical Services, Inc.'s net margin of 15.71%. West Pharmaceutical Services, Inc.'s return on equity of 17.9% beat Boston Scientific Corp.'s return on equity of 11.49%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.35.66% $1.82 $3.2B BSXBoston Scientific Corp.62.79% $0.53 $34.7B -
What do Analysts Say About WST or BSX?
West Pharmaceutical Services, Inc. has a consensus price target of $316.36, signalling upside risk potential of 24.97%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.27 which suggests that it could grow by 14.92%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Boston Scientific Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.9 2 0 BSXBoston Scientific Corp.24 3 0 -
Is WST or BSX More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.054, which suggesting that the stock is 5.449% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.655, suggesting its less volatile than the S&P 500 by 34.544%.
-
Which is a Better Dividend Stock WST or BSX?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 0.33%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays -12% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WST or BSX?
West Pharmaceutical Services, Inc. quarterly revenues are $766.2M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. West Pharmaceutical Services, Inc.'s net income of $131.8M is lower than Boston Scientific Corp.'s net income of $795M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 37.60x while Boston Scientific Corp.'s PE ratio is 64.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.20x versus 8.72x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.20x 37.60x $766.2M $131.8M BSXBoston Scientific Corp.8.72x 64.37x $5.1B $795M
-
Which has Higher Returns WST or ISRG?
Intuitive Surgical, Inc. has a net margin of 17.2% compared to West Pharmaceutical Services, Inc.'s net margin of 27.22%. West Pharmaceutical Services, Inc.'s return on equity of 17.9% beat Intuitive Surgical, Inc.'s return on equity of 15.98%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.35.66% $1.82 $3.2B ISRGIntuitive Surgical, Inc.66.31% $1.81 $18B -
What do Analysts Say About WST or ISRG?
West Pharmaceutical Services, Inc. has a consensus price target of $316.36, signalling upside risk potential of 24.97%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $582.10 which suggests that it could grow by 24.68%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.9 2 0 ISRGIntuitive Surgical, Inc.15 8 1 -
Is WST or ISRG More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.054, which suggesting that the stock is 5.449% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.613, suggesting its more volatile than the S&P 500 by 61.328%.
-
Which is a Better Dividend Stock WST or ISRG?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 0.33%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays -12% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WST or ISRG?
West Pharmaceutical Services, Inc. quarterly revenues are $766.2M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.4B. West Pharmaceutical Services, Inc.'s net income of $131.8M is lower than Intuitive Surgical, Inc.'s net income of $664.2M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 37.60x while Intuitive Surgical, Inc.'s PE ratio is 65.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.20x versus 18.57x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.20x 37.60x $766.2M $131.8M ISRGIntuitive Surgical, Inc.18.57x 65.11x $2.4B $664.2M
-
Which has Higher Returns WST or MASI?
Masimo Corp. has a net margin of 17.2% compared to West Pharmaceutical Services, Inc.'s net margin of 12.11%. West Pharmaceutical Services, Inc.'s return on equity of 17.9% beat Masimo Corp.'s return on equity of -21.09%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.35.66% $1.82 $3.2B MASIMasimo Corp.62.9% $0.94 $1.7B -
What do Analysts Say About WST or MASI?
West Pharmaceutical Services, Inc. has a consensus price target of $316.36, signalling upside risk potential of 24.97%. On the other hand Masimo Corp. has an analysts' consensus of $187.57 which suggests that it could grow by 27.44%. Given that Masimo Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Masimo Corp. is more attractive than West Pharmaceutical Services, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.9 2 0 MASIMasimo Corp.4 2 0 -
Is WST or MASI More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.054, which suggesting that the stock is 5.449% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.87%.
-
Which is a Better Dividend Stock WST or MASI?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 0.33%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays -12% of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WST or MASI?
West Pharmaceutical Services, Inc. quarterly revenues are $766.2M, which are larger than Masimo Corp. quarterly revenues of $370.9M. West Pharmaceutical Services, Inc.'s net income of $131.8M is higher than Masimo Corp.'s net income of $44.9M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 37.60x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.20x versus 4.31x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.20x 37.60x $766.2M $131.8M MASIMasimo Corp.4.31x 116.80x $370.9M $44.9M
-
Which has Higher Returns WST or PODD?
Insulet Corp. has a net margin of 17.2% compared to West Pharmaceutical Services, Inc.'s net margin of 3.47%. West Pharmaceutical Services, Inc.'s return on equity of 17.9% beat Insulet Corp.'s return on equity of 19.28%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.35.66% $1.82 $3.2B PODDInsulet Corp.70.31% $0.32 $2.9B -
What do Analysts Say About WST or PODD?
West Pharmaceutical Services, Inc. has a consensus price target of $316.36, signalling upside risk potential of 24.97%. On the other hand Insulet Corp. has an analysts' consensus of $355.17 which suggests that it could grow by 1.61%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Insulet Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Insulet Corp..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.9 2 0 PODDInsulet Corp.16 3 0 -
Is WST or PODD More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.054, which suggesting that the stock is 5.449% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.365, suggesting its more volatile than the S&P 500 by 36.492%.
-
Which is a Better Dividend Stock WST or PODD?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 0.33%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays -12% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WST or PODD?
West Pharmaceutical Services, Inc. quarterly revenues are $766.2M, which are larger than Insulet Corp. quarterly revenues of $649.1M. West Pharmaceutical Services, Inc.'s net income of $131.8M is higher than Insulet Corp.'s net income of $22.5M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 37.60x while Insulet Corp.'s PE ratio is 106.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.20x versus 10.86x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.20x 37.60x $766.2M $131.8M PODDInsulet Corp.10.86x 106.36x $649.1M $22.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CRM’s Share Buyback a Buy Signal?
CRM software giant Salesforce (NYSE:CRM) has been vigorously buying back…
Is Lululemon Stock on Sale?
Picture this, you’re in your favorite yoga studio, stretching into…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 57x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 36x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Alerts
Buy
84
OCTO alert for Sep 9
Eightco Holdings, Inc. [OCTO] is down 25.93% over the past day.
Sell
34
GGAL alert for Sep 9
Grupo Financiero Galicia SA [GGAL] is up 2.06% over the past day.
Sell
13
BMA alert for Sep 9
Banco Macro SA [BMA] is up 0.16% over the past day.
